国家糖尿病预防计划在真实世界中的成本效益:一项为期2年的前瞻性研究
在雇主提供医保的大规模在职人群中,评估国家糖尿病预防计划(NDPP)对糖尿病前期的真实世界成本效益。采用双重差分分析5,948名成人(入组575人,未入组5,373人)的理赔与调查数据,发现入组者2年总直接医疗成本平均减少4,552美元(95%CI -13,231,2,014),EQ-5D-5L效用评分与质量调整生命年无差异;入组在2年内有88%概率节省费用,在每QALY 100,000美元支付意愿阈值下有84%概率具成本效益。结论为入组NDPP可能节省费用。
要点
- NDPP入组者2年总直接医疗成本平均减少4,552美元(95%CI -13,231,2,014)。
- 成本节省主要与住院、门诊就诊和急诊就诊相关。
- 入组者2年EQ-5D-5L效用评分与QALYs较未入组者无差异。
核心结论
- 在真实世界糖尿病前期人群中,入组NDPP可能节省费用。
研究设计与样本
- 前瞻性研究,采用双重差分分析,纳入5,948名糖尿病前期成人,其中入组NDPP 575人、未入组5,373人。
- 使用个体水平医保理赔与调查数据,评估入组前一年及之后2年的直接医疗成本、基线/1年/2年的EQ-5D-5L效用评分及2年QALYs。
- 采用倾向评分加权校正自选择偏倚,多重插补处理缺失数据,自举法生成置信区间。
- 采用医疗保健部门视角,成本和QALYs按每年3%贴现,成本以2020年美元表示。
主要发现
- 与未入组者相比,每名NDPP入组者2年总直接医疗成本平均减少4,552美元(95%CI -13,231,2,014)。
- 成本节省主要与住院、门诊就诊和急诊就诊相关。
- 与未入组者相比,每名入组者2年EQ-5D-5L效用评分无差异,2年QALYs也无差异。
- 不确定性分析发现,入组NDPP节省费用的概率为88%,在每QALY 100,000美元支付意愿阈值下2年内具成本效益的概率为84%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated the real-world cost-effectiveness of the National Diabetes Prevention Program (NDPP) for people with prediabetes in a large workforce with employer-sponsored health insurance. RESEARCH DESIGN AND METHODS: We performed difference-in-differences analyses using individual-level health insurance claims and survey data for 5,948 adults with prediabetes who enrolled (n = 575) or did not enroll (n = 5,373) in the NDPP to assess NDPP's effects on health economic outcomes. We assessed direct medical costs for the year before the NDPP enrollment/index date and for 2 years thereafter; EuroQol 5-dimension 5-level questionnaire (EQ-5D-5L) utility scores at baseline, 1 year, and 2 years; and quality-adjusted life-years (QALYs) over 2 years. We used propensity score weighting to adjust for potential bias due to self-selection for enrollment, multiple imputation to handle missing data, and bootstrapping to produce CIs. We adopted a health care sector perspective and discounted costs and QALYs at 3% annually. Costs were expressed in 2020 U.S. dollars. RESULTS: Compared with nonenrollees, each NDPP enrollee had an average reduction of $4,552 (95% CI -13,231, 2,014) in 2-year total direct medical costs. Cost savings were primarily related to hospitalizations, outpatient visits, and emergency room visits. Compared with nonenrollees, each enrollee had no difference in EQ-5D-5L utility scores at 2 years or QALYs gained over 2 years. The uncertainty analyses found that enrollment in the NDPP had an 88% probability of saving money and 84% probability of being cost-effective at a willingness-to-pay threshold of $100,000 per QALY gained over 2 years. CONCLUSIONS: In this real-world population with prediabetes, enrollment in the NDPP was likely to provide cost savings.
引用
- Kuo S, Ye W, Wang D, et al. Cost-effectiveness of the National Diabetes Prevention Program: A Real-world, 2-Year Prospective Study. Diabetes Care. 2025. PMID: 39565893. doi:10.2337/dc24-1110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。